Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Monoclonal antibody

Also known as MK-3475A

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma, Cervical Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Solid Tumors, Breast Cancer, Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (15)
US
  • Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test and who have received one or two prior systemic treatment regimens
    Outside this platform's coverageFDA label
  • Malignant Pleural Mesothelioma (MPM): KEYTRUDA QLEX in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPMOutside this platform's coverageFDA label
  • Head and Neck Squamous Cell Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. KEYTRUDA QLEX, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of adult patients with metastatic or with u
    FDA label
  • Urothelial Cancer KEYTRUDA QLEX, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA QLEX, as a single agent, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA QLEX, in combination wit
    FDA label
  • Esophageal Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients w
    Outside this platform's coverageFDA label
  • Hepatocellular Carcinoma KEYTRUDA QLEX is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.FDA label
  • Biliary Tract Cancer KEYTRUDA QLEX, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).FDA label
  • Merkel Cell Carcinoma KEYTRUDA QLEX is indicated for the treatment of adult and pediatric patients 12 years and older with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).FDA label
  • Endometrial Carcinoma KEYTRUDA QLEX, in combination with carboplatin and paclitaxel, followed by KEYTRUDA QLEX as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. KEYTRUDA QLEX, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [
    FDA label
  • Tumor Mutational Burden-High Cancer KEYTRUDA QLEX is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options . This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approva
    Outside this platform's coverageFDA label
  • Ovarian Cancer KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
    FDA label
  • Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA QLEX is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] .
    Outside this platform's coverageFDA label
  • Cutaneous Squamous Cell Carcinoma KEYTRUDA QLEX is indicated for the treatment of adult patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.Outside this platform's coverageFDA label
Product first approved 2025
JP
  • Subcutaneous administration across all indications for which IV pembrolizumab is approved in Japan (Keytruda Qlex; Keyject)
Product first approved 2026onclive.com
EU
  • KEYTRUDA SC, subcutaneous pembrolizumab with berahyaluronidase alfa, all 33 adult KEYTRUDA indications in the EU
Product first approved 2025americanpharmaceuticalreview.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Bladder Cancer
NCT07829783 · Merck Sharp & Dohme LLC
2026-10-23 – 2036-09-25 · Bladder Cancer
What this study did
Colorectal Cancer
Non-Small Cell Lung Cancer
NCT07190248 · Merck Sharp & Dohme LLC
2025-10-08 – 2032-08-06 · Non-small Cell Lung Cancer
What this study did
NCT06698042 · Merck Sharp & Dohme LLC
2024-11-21 – 2027-04-17 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
Solid Tumors
NCT03486873 · Merck Sharp & Dohme LLC
2018-08-21 – 2043-08-04 · Solid Tumors, Hematologic Malignancies
What this study did
Other / comorbidity
NCT07919899 · Sanofi
2026-11-30 – 2028-07-25 · Dermatitis Atopic
What this study did
Phase 2 (3)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06504394 · Merck Sharp & Dohme LLC
2024-10-14 – 2028-11-08 · Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
What this study did
Phase 1 (2)
Solid Tumors
Other / comorbidity
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT07431827 · Merck Sharp & Dohme LLC
2026-03-18 – 2039-10-26 · Non-small Cell Lung Cancer
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex): this drugApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Keytruda Qlex (Pembrolizumab berahyaluronidase alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
March 2028 (1)
Phase 2Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06041802 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Dermatitis AtopicNot yet recruiting
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent …Active not recruiting
Est. primary completion 2028-11-08 · NCT06504394 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-07 · NCT07190248 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-04-05 · NCT07750158 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
Phase 3Solid TumorsRecruiting
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 September 2025ApprovalFDA approves Keytruda Qlex (subcutaneous pembrolizumab)
US, FDA · Merck · Source ↗
19 November 2024Topline resultSubcutaneous pembrolizumab Phase 3 meets primary endpoints
Merck · Source ↗